Eddy S. Yang

7.8k total citations · 1 hit paper
167 papers, 4.4k citations indexed

About

Eddy S. Yang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eddy S. Yang has authored 167 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 77 papers in Molecular Biology and 62 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eddy S. Yang's work include PARP inhibition in cancer therapy (41 papers), DNA Repair Mechanisms (34 papers) and Prostate Cancer Treatment and Research (27 papers). Eddy S. Yang is often cited by papers focused on PARP inhibition in cancer therapy (41 papers), DNA Repair Mechanisms (34 papers) and Prostate Cancer Treatment and Research (27 papers). Eddy S. Yang collaborates with scholars based in United States, Canada and China. Eddy S. Yang's co-authors include Somaira Nowsheen, Alice N. Weaver, James A. Bonner, Deborah Della Manna, Fen Xia, Courtney M. Peterson, Éric Ravussin, Robbie A. Beyl, Humaira Jamshed and Kerry L. Burnstein and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Eddy S. Yang

162 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans

2019 449 citations Eddy S. Yang et al. profile →

Peers

Countries citing papers authored by Eddy S. Yang

Since Specialization

Citations

This map shows the geographic impact of Eddy S. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eddy S. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eddy S. Yang more than expected).

Fields of papers citing papers by Eddy S. Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eddy S. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eddy S. Yang. The network helps show where Eddy S. Yang may publish in the future.

Co-authorship network of co-authors of Eddy S. Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Eddy S. Yang. A scholar is included among the top collaborators of Eddy S. Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eddy S. Yang. Eddy S. Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reported Early Clinical Outcomes of Forward-Planned Multileaf Collimator-Based 3-Dimensional Conformal Spatially Fractionated Radiation Therapy Technique for Large and Bulky Tumors 2025 ·International Journal of Radiation OncologyBiologyPhysics ·James A. Knight, (unknown), (unknown), Mark E. Bernard, Denise Fabian, Mahesh Kudrimoti, Weisi Yan, William St Clair, Eddy S. Yang, Damodar Pokhrel	0
2	Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor 2024 ·Cancer Letters ·(unknown), Jeremy A. Johnson, Aman Chauhan, Jong Cheol Jeong, (unknown), (unknown), Heidi L. Weiss, Courtney M. Townsend, Jörg Schrader, Lowell Anthony, Eddy S. Yang, (unknown), Piotr Rychahou	5
3	Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Diana Kimono, (unknown), Eddy S. Yang, Tomas Kirchhoff, Amrutesh S. Puranik, Jeffrey S. Weber	1
4	Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study 2024 ·JCO Precision Oncology ·Eugene R. Ahn, Michael Rothe, Pam K. Mangat, Elizabeth Garrett‐Mayer, Carmen Calfa, Ajjai Alva, (unknown), Olatunji B. Alese, Efrat Dotan, Omid Hamid, Eddy S. Yang, Alissa Marr, Martin Palmer, (unknown), Kathleen J. Yost, (unknown), (unknown), Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky	1
5	BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine 2024 ·Cancer Letters ·Aubrey L. Miller, (unknown), (unknown), Dongquan Chen, (unknown), Md. Iqbal Hossain, (unknown), Shaida A. Andrabi, Hengbin Wang, Eddy S. Yang, Donald J. Buchsbaum, Robert C.A.M. van Waardenburg, Susan L. Bellis, Karina J. Yoon	7
6	An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases 2022 ·JCI Insight ·(unknown), Joshua C. Anderson, Zongliang Yue, Thanh Nguyen, (unknown), Catherine P. Langford, Jelai Wang, James Rowland, Chuan Xing, Fady M. Mikhail, Xiangqin Cui, (unknown), Ryan Bash, Kevin J. Lee, Eddy S. Yang, Anita B. Hjelmeland, C. Ryan Miller, Jake Y. Chen, G. Yancey Gillespie, Christopher D. Willey	12
7	Poly(N-vinylpyrrolidone)-block-Poly(dimethylsiloxane)-block-Poly(N-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast Cancers 2022 ·ACS Applied Bio Materials ·Yiming Yang, Veronika Kozlovskaya, Zhuo Zhang, Chuan Xing, (unknown), (unknown), Shuo Qian, Jun Zhang, Jason M. Warram, Eddy S. Yang, Eugenia Kharlampieva	20
8	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent 2021 ·Molecular Cancer Therapeutics ·Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, (unknown), David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru Sonpavde	6
9	The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer 2021 ·Cancers ·Aubrey L. Miller, Patrick L. Garcia, (unknown), (unknown), (unknown), Dongquan Chen, Eddy S. Yang, Robert C.A.M. van Waardenburg, Karina J. Yoon	20
10	A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma 2021 ·Radiotherapy and Oncology ·Eddy S. Yang, Éric Deutsch, Mehmet Altan, Jérôme Fayette, Yungan Tao, Lisle Nabell, Sharon A. Spencer, (unknown), (unknown), Wei Zhang, Scott M. Hynes, (unknown), (unknown), William Nassib William	19
11	CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma 2020 ·Molecular Cancer Therapeutics ·Ling Zeng, Anatoly Nikolaev, Chuan Xing, (unknown), Eddy S. Yang	31
12	Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma 2018 ·Molecular Cancer Research ·Rebecca C. Arend, Angelina I. Londoño, (unknown), Haller J. Smith, Zachary C. Dobbin, Ashwini A. Katre, Alba Martínez, Eddy S. Yang, Ronald D. Alvarez, Warner K. Huh, Kerri S. Bevis, J. Michael Straughn, Jacob M. Estes, Lea Novak, David K. Crossman, Sara J. Cooper, Charles N. Landen, Charles A. Leath	47
13	Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma 2017 ·Molecular Cancer Therapeutics ·Ling Zeng, (unknown), Tiffiny S. Cooper, Alice N. Weaver, Eddy S. Yang	40
14	Notch Signaling Activation Is Associated with Patient Mortality and Increased FGF1-Mediated Invasion in Squamous Cell Carcinoma of the Oral Cavity 2016 ·Molecular Cancer Research ·Alice N. Weaver, (unknown), Tiffiny S. Cooper, (unknown), Shi Wei, Akinyemi I. Ojesina, Eben L. Rosenthal, Eddy S. Yang	33
15	Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma 2016 ·SHILAP Revista de lepidopterología ·(unknown), Andrew M. McDonald, Eddy S. Yang, Rojymon Jacob, Soroush Rais‐Bahrami, Jeffrey W. Nix, John B. Fiveash	5
16	Endoglin (CD105) Contributes to Platinum Resistance and Is A Target for Tumor-Specific Therapy in Epithelial Ovarian Cancer 2012 ·Clinical Cancer Research ·Angela Ziebarth, Somaira Nowsheen, Adam D. Steg, Monjri M. Shah, Ashwini A. Katre, Zachary C. Dobbin, Hee‐Dong Han, Gabriel Lopez‐Berestein, Anil K. Sood, Michael Conner, Eddy S. Yang, Charles N. Landen	51
17	Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition 2012 ·Cancer Research ·Eddy S. Yang, Somaira Nowsheen, Mohammad Aminur Rahman, Rebecca S. Cook, Fen Xia	24
18	MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma 2012 ·Clinical Cancer Research ·(unknown), Joshua C. Anderson, Christine W. Duarte, Tapan Mehta, Somaira Nowsheen, Patricia H. Hicks, Alexander C. Whitley, (unknown), Raymond O. McCubrey, (unknown), (unknown), James A. Bonner, G. Yancey Gillespie, Eddy S. Yang, Christopher D. Willey	47
19	p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage 2011 ·Cancer Research ·Juhong Jiang, Eddy S. Yang, Guochun Jiang, Somaira Nowsheen, Hong Wang, Tong Wang, Yihan Wang, Dean Billheimer, A. Bapsi Chakravarthy, Melissa A. Brown, Bruce G. Haffty, Fen Xia	61
20	Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells 2008 ·Cancer Research ·Liping Li, Hong Wang, Eddy S. Yang, Carlos L. Arteaga, Fen Xia	102

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact